Autopsy report · NCT02274740

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

“Sponsor decision not related to safety reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 4 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Sanofi

Sponsor type

Industry

Conditions

Type II Diabetes Mellitus

Interventions

LIXISENATIDE AVE0010; metformin

Participants

2

Trials that died the same way

• Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
  “Sponsor decision not related to safety concerns” (96% match in meaning)
• A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts
  “Sponsor decision, not safety related” (92% match in meaning)
• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
  “Sponsor decision, not for safety reasons.” (92% match in meaning)
• A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
  “Sponsor decision; Not a safety decision” (91% match in meaning)
• Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
  “Sponsor decision (not due to safety concerns)” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.